Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Sutro Biopharma, a clinical-stage oncology company, announced that CEO Bill Newell will participate in two upcoming investor conferences. The first is the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:30 a.m. ET in New York. The second is the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 3:40 p.m. ET, conducted virtually. Presentations will be accessible on the company’s website for 30 days post-event. Sutro is known for pioneering antibody drug conjugates and currently has two ADCs in clinical trials.
Sutro Biopharma (NASDAQ: STRO) reported a revenue of $25.1 million for Q3 2022, up from $8.5 million the previous year, primarily due to collaboration payments. Cash reserves totaled $287.3 million, providing a runway into H1 2024. Key highlights include the acceptance of STRO-002 data for presentation at ASH 2022 and ongoing clinical studies for other assets. The company expects to release additional data on STRO-002's efficacy in late 2022, underlining the potential for accelerated FDA approval in ovarian cancer.
Sutro Biopharma announced promising results from its compassionate use program for STRO-002, an antibody drug conjugate targeting acute myeloid leukemia (AML) in children. Data will be shared at the 64th American Society of Hematology Annual Meeting on December 10, 2022. Highlights included significant anti-leukemic activity and a number of complete responses among patients with a rare form of AML, typically resistant to standard treatments. CEO Bill Newell expressed optimism about STRO-002's potential impact in pediatric oncology.
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company, announced that CEO Bill Newell will present at two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 11:35 a.m. ET in Rancho Palos Verdes, CA. The second is the Jefferies London Healthcare Conference on November 17, 2022, at 12:55 p.m. GMT in London. Presentations will be accessible on the company’s website, with archived replays available for 30 days post-event.
Sutro Biopharma (NASDAQ: STRO) announced that Chief Medical Officer, Arturo Molina, will leave the company effective November 4, 2022, to pursue other opportunities. CEO Bill Newell will oversee clinical activities in the interim while the search for a new CMO continues. Sutro's pipeline includes six clinical-stage product candidates, with a focus on STRO-002, aimed at advanced ovarian cancer, highlighting an active development strategy despite the leadership change.
Sutro Biopharma, a clinical-stage oncology company, announced its CEO Bill Newell will present at the 2022 Wells Fargo Healthcare Conference on September 9, 2022, at 10:25 a.m. ET in Boston. The presentation can be accessed via the Investor Relations section of their website, with an archived replay available for 30 days following the event. Sutro is focused on developing innovative antibody drug conjugates (ADCs), including STRO-002 for ovarian and endometrial cancers and STRO-001 for B-cell malignancies, alongside collaborations with major pharmaceutical companies.
Sutro Biopharma (NASDAQ: STRO) announced on August 16, 2022, that its Compensation Committee granted 63,000 Restricted Stock Units (RSUs) to three new employees as an inducement for their employment. The RSUs will vest over four years, with 25% vesting annually, contingent upon continued service. Sutro specializes in developing antibody drug conjugates for oncology and is advancing multiple clinical-stage products, including STRO-002 and STRO-001, targeting various cancers. The grants were in accordance with Nasdaq Listing Rule 5635(c)(4).
Sutro Biopharma, Inc. (NASDAQ: STRO) reported strong collaboration developments and financial results for Q2 2022. A partnership with Astellas involves $90 million upfront and potential milestones worth $422.5 million per product. The company received a $10 million milestone payment from Merck after dosing the first patient in a Phase 1 study. Sutro's cash and equivalents stand at $191.6 million, expected to fund operations into H1 2024. Though revenues slightly increased to $28.1 million, operating expenses rose to $47.5 million, impacted by higher R&D costs. Discussions with the FDA suggest an accelerated approval pathway for STRO-002.
Sutro Biopharma, Inc. (NASDAQ: STRO) announced that CEO Bill Newell will present at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 2:20 p.m. ET. The discussion will focus on antibody drug conjugates (ADCs), a key area of Sutro's innovation in oncology. The presentation will be accessible on the company's Investor Relations page, with an archived replay available for 30 days post-event. Sutro's pipeline includes two ADCs in clinical trials, STRO-002 for ovarian and endometrial cancers and STRO-001 for B-cell malignancies.
Sutro Biopharma (NASDAQ: STRO) announced that the first patient has been dosed in a Phase 1 study of a novel therapeutic candidate developed in collaboration with Merck. This milestone triggers a $10 million payment from Merck to Sutro. The investigational drug is designed for cancer treatment, leveraging Sutro's proprietary platforms for biologics. Sutro is also advancing other ADCs in clinical trials, targeting various cancers. CEO Bill Newell emphasized the synergy between Sutro and Merck in advancing immuno-oncology therapies.